Cure Sanfilippo Foundation的动态

Embracing Science, Social Media and Solidarity: 2025 is a year of hope and action. For Cervical Cancer Elimination Consortium - India (CCEC-I) the new year has begun with radiant hopes and deep ambitions. We had our first partner’s meeting on January 10 and our commitment of to advocate for, demonstrate and document an integrated strategy for cervical cancer elimination in India remains strong. 2025 is going to be a year of action on cervical cancer elimination in India. With strong commitment from Central government, high demand from State Governments, improved availability of diagnostics, and vaccines and a very strong leadership from India’s Prime Minister, we do expect that the diagnosis, treatment, vaccination coverage for cervical cancer in India will improve. The consortium partners are ready to support the State and Central governments to intensify their cervical cancer elimination activities. CCEC-I will also create platforms for exchange learnings and lessons. For example, one of the countries that has addresses cervical cancer elimination with success is Australia. We will work the University of Sydney to create a learning exchange platform particularly focusing on successful community mobilization though strategic awareness, inclusiveness and education initiatives. We will exchange lessons with agencies in Bangladesh where the cervical cancer vaccine has been launched recently. Our approach to reinforce empowering communities with knowledge about cervical cancer – the disease, prevention, treatment and its possible elimination goal will be strategic. We will focus on 3 S s. We will speak Science, and evidence-based science. We will use the Social Media platforms to amplify our reach to all and particularly the youths of our country. And finally, we will commit to Solidarity between all partners, agencies and the community in making Cervical Cancer Elimination a national goal. We have a cervical cancer elimination panel discussion on January 17 between 3 PM to 4 PM. The webinar is being co-convened by CHIP Foundation and ECHO focusing on the importance of prevention, early detection, and vaccination against HPV – the primary cause of "Cervical Cancer". Please register, request your colleagues to register and let us have an inclusive dialogue on how we can join hands for a Cervical Cancer Mukt Bharat. To register, please follow the link below. https://lnkd.in/gnQbg4hb Sandeep Bhalla Ravi Mehrotra, MD, DPhil Mridu Gupta Anila Goswami Prof. Sanjay Dhir Ysha Agrawal Kaushik Ghosh Prem Singh Jhpiego ECHO India CHIP Foundation India CAPED India Marissa Malchione A/Prof Meru Sheel Shailendra Sawleshwarkar American Cancer Society Meenu Anand, MBA, MPH

Embracing Science, Social Media and Solidarity: 2025 is a year of hope and action. For Cervical Cancer Elimination Consortium - India (CCEC-I) the new year has begun with radiant hopes and deep ambitions. We had our first partner’s meeting on January 10 and our commitment of to advocate for, demonstrate and document an integrated strategy for cervical cancer elimination in India remains strong. 2025 is going to be a year of action on cervical cancer elimination in India. With strong commitment from Central government, high demand from State Governments, improved availability of diagnostics, and vaccines and a very strong leadership from India’s Prime Minister, we do expect that the diagnosis, treatment, vaccination coverage for cervical cancer in India will improve. The consortium partners are ready to support the State and Central governments to intensify their cervical cancer elimination activities. CCEC-I will also create platforms for exchange learnings and lessons. For example, one of the countries that has addressed cervical cancer elimination with success is Australia. We will work with the University of Sydney to create a learning exchange platform particularly focusing on successful community mobilization though strategic awareness, inclusiveness and education initiatives. We will exchange lessons with agencies in Bangladesh where the cervical cancer vaccine has been launched recently. Our approach to reinforce empowering communities with knowledge about cervical cancer – the disease, prevention, treatment and its possible elimination goal will be strategic. We will focus on 3 S s. We will speak Science, and evidence-based science. We will use the Social Media platforms to amplify our reach to all and particularly the youths of our country. And finally, we will commit to Solidarity between all partners, agencies and the community in making Cervical Cancer Elimination a national goal. We have a cervical cancer elimination panel discussion on January 17 between 3 PM to 4 PM. The webinar is being co-convened by CHIP Foundation and ECHO focusing on the importance of prevention, early detection, and vaccination against HPV – the primary cause of "Cervical Cancer". Please register, request your colleagues to register and let us have an inclusive dialogue on how we can join hands for a Cervical Cancer Mukt Bharat. To register, please follow the link below. https://lnkd.in/gnQbg4hb Sandeep Bhalla Ravi Mehrotra, MD, DPhil Mridu Gupta Anila Goswami Prof. Sanjay Dhir Ysha Agrawal Kaushik Ghosh Prem Singh Jhpiego ECHO India CHIP Foundation India CAPED India Marissa Malchione A/Prof Meru Sheel Shailendra Sawleshwarkar American Cancer Society Meenu Anand, MBA, MPH

The Communication Team of Syreon Research Institute has completed an educational video for the STREXIT 2 Project, an initiative to advance the understanding and treatment of retroperitoneal sarcomas. ?? These rare cancers are notoriously refractory to treatment and carry a poor prognosis. Currently, surgery is the standard approach to managing primary disease, but there is an urgent need to explore additional treatment options. The STREXIT2 project is designed to complement the ongoing phase III EORTC - European Organisation for Research and Treatment of Cancer clinical trial, STRASS2 to investigate the added value of neoadjuvant chemotherapy before surgery for high-risk retroperitoneal sarcoma. The project includes a health economics analysis to determine optimal treatment strategies, potentially setting new standards of care. Discover more about the STREXIT 2 Project by watching our video and join us in raising awareness about sarcomas! https://lnkd.in/dXJSSdGt #SarcomaAwarenessMonth #SyreonResearchInstitute #STREXIT2 #EORTC #CancerResearch

Even with the Memorial Day holiday coming up, I'm already looking ahead to end of next week and the start of the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. It's always a busy and productive time, and this year's meeting includes a diverse set of presentations that I am excited to be a part of. In addition to being an invited panelist for the Caris Life Sciences Fellows Forum focused on career paths for early-career investigators and trainees, I will be a speaker at the Education Session taking place Saturday, June 1 from 1:15-2:30 pm, focused on Unlocking the Potential: Biomarkers of Response to Antibody–Drug Conjugates. The title of my talk will be: Dynamic Evaluation of Biomarkers in Patients Treated With?Antibody-Drug Conjugates (ADCs). Looking forward to this session, as it focuses on an fast-growing form of developmental therapeutic class of cancer drugs. Join us in Hall D1 if you'll be at #ASCO24! with Chair and Speaker Dr. Giuseppe Curigliano, speaker Dr. Patricia LoRusso, Education Chair Dr. Thomas LeBlanc https://lnkd.in/gmADupWu #oncology #oncologist #cancer #cancertreatment #developmentaltherapeutics #tumorbiology #molecularlytargetedagents #cancerbiology #cancerbio #cancertherapy #cancertherapeutics #medicine #physicianscientist #mdphd #medicine #medical #ASCO #science #cancerscience #laboratory #lablife #medicalife

?? ExoSplice revolutionizes pseudo-exon correction ?? Alternative splicing is a fundamental mechanism for regulating gene expression, enabling the production of multiple protein isoforms from a single gene. However, anomalies in this process, such as the inclusion of pseudo-exons, can lead to serious dysfunction. Excluding these pseudo-exons using exon-skipping approaches is a real solution, and ExoSplice is here to help. #ExonSkipping #AON #Therapy #Genetics #Genomics #Bioinformatics #Innovation #PseudoExon

? Looking Back at 2024: A Key Year for Genomnis ? ? As 2025 begins, we wanted to share the highlights of 2024, a year of innovation and growth for Genomnis. ? ?? Launch of Our New Website ? A completely redesigned website, more intuitive and informative, providing a detailed overview of our solutions and tools to better serve our users. ? ?? Introducing Our New CANDICE Solution Collaborative ANnotation Database with an Interpretation and Classification Expert system ? CANDICE is an innovative tool for the annotation and analysis of genetic variants and CNVs, transforming research and diagnostic processes. It provides an enhanced user experience and advanced features that enable researchers, clinicians and healthcare professionals to quickly identify relevant genetic variations for informed decision-making. ? CANDICE offers the possibility to perform complex analyses on data from NGS or CGH Array, in VCF format (SNVs, CNVs) or in the format provided by Agilent's Cytogenomics software (CNVs). Beyond the simple analysis of the index case, the system allows the analysis of trios or complex families with the construction of a family tree. Furthermore, thanks to its advanced search module, CANDICE allows the creation of cohorts of patients that can then be analyzed to detect common variants of interest or common genes, and to perform Burden tests. ? In addition, one of its key innovations is automated SNV and CNV classification, which streamlines and accelerates the interpretation of genetic data, making it a powerful resource for healthcare professionals. ? Interested in learning more? You can request a demo on our website to explore the full potential of CANDICE. ?? https://lnkd.in/eDMmW3-M ? ?? Major Update of Our ExoSplice Tool ? ExoSplice's algorithms have been carefully improved and revised to provide users with even greater accuracy and performance. Researchers and clinicians now have access to a fast, reliable and precise solution for developing targeted therapeutic strategies. ? We have also launched a new module designed to revolutionize pseudo-exon correction. Using cutting-edge algorithms and an intuitive interface, ExoSplice automates the generation and prioritization of antisense oligonucleotides (AONs), customized for any given pseudo-exon. ? ? Thank You! We would like to thank our partners, customers and teams for their trust and support throughout 2024. We look forward to continuing this exciting journey with you in 2025! #Innovation #Genetics #Genomics #Bioinformatics #CANDICE #CNVanalysis #CNVs #ExoSplice #ExonSkipping #AON #Therapy #PseudoExon Marseille Innovation

#WebinarOfTheWeek ? We invite you to join our upcoming Masterclass session that will provide actionable insights into advanced immune cell phenotyping and functional characterization techniques.? ? Unlocking Predictive Insights with Functional Markers Tuesday, October 29 8:00 am PT | 11:00 am ET Register at the link attached. Why attend? ??? ? ->Learn how to streamline biomarker discovery for immune monitoring studies. ->Discover how to analyze cytokine activity and immune checkpoint expression effectively. ->Overcome technical challenges in building large parameter panels. ->Learn how to combine modular panels for application-specific immunophenotyping and functional evaluation of human oncology samples ? #immunology #phenotyping #microfluidics #realtimepcr

As the Principal Investigator of the #EUTRAIN EU ???? Funded project, I am delighted to announce our final workshop on June 21st (9am to 5pm), held in?PariSanté Campus, and will spotlight the latest advancements in monitoring techniques for kidney transplant patients. The workshop is organized by?Inserm Transfert?and sponsored by?ESOT - European Society for Organ Our program will cover a comprehensive range of topics, including: ·??????An overview of the EU-TRAIN project’s goals and accomplishments??? ·??????Innovations in non-invasive biomarkers for monitoring??? ·??????The application of precision medicine in transplantation??? ·??????Discussion on quality-of-life outcomes ?? ·??????Results from the inaugural RCT on non-invasive monitoring techniques??? Register by please respond to the link below Full program here -> https://lnkd.in/dMYHiEkN Alex, for The EUTRAIN Consortium Agence du Numérique en Santé AGENCE DE LA BIOMEDECINE Inserm AP-HP, Assistance Publique - H?pitaux de Paris Lise ALTER Bruno Bonnell Antoine Tesniere Matthieu Landon Eric Vibert, MD, PhD Alumni Network PARCC Eurotransplant Ministère de l'Enseignement supérieur et de la Recherche NanoString Technologies, Inc. Yann Bubien Renaloo : la voix des malades du rein Université Paris Cité SFT - Société Francophone de Transplantation ECRIN (European Clinical Research Infrastructure Network)

Register now! This online workshop will be hosted by the Necker Hospital in Paris, France, and will try to define the role of induction in ABO-incompatible transplantation and to highlight the complexity of diagnosis in some cases. This will be summarised in a short presentation together with an introduction of the role of induction in HIR patients. The final part will be devoted to a complex case report outlining how difficult it is to decipher the role of the main induction therapies we rely on. #ESOTeducation

The countdown is on. Next week, I'm heading to Chicago for the American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO24). It's one of the most significant events in the oncology world, bringing together a global community of researchers, clinicians, advocates, and patients in the fight against cancer. For me, #ASCO24 is more than just a conference; it's a chance to: - Dive into the Latest Research:?Thousands of abstracts will?be presented, showcasing cutting-edge advancements across all aspects of cancer care. I'm eager to learn about new therapies, diagnostic approaches, and breakthroughs that can transform patients' lives. Discussing the evolving landscape of cancer treatment is crucial for staying updated on the latest developments and best practices in patient care. - Connect with Experts:?Meeting and exchanging ideas with leading oncologists, scientists, and industry innovators is an invaluable experience. It fosters collaboration and fuels inspiration for advancing cancer care. - Share Our Recent Developments: Zephyr AI team will present a poster and share our findings on the "Evaluation of a Novel Machine Learning Method for PARP Inhibitor Sensitivity Prediction Using Real-World Data." Abstract # 5583 / Poster Bd # 454, presented by Emily Vucic et al., June 3rd, 9 am—12 pm: https://lnkd.in/g8wKqB8v In the meantime, what are you most interested in learning about from #ASCO24? Share your thoughts and questions. See you in Chicago!